ClinicalTrials.gg
RecruitingNCT04792463Updated Oct 16, 2026

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

An observational study in Uveal Melanoma, Cutaneous Melanoma and BAP1 Gene Mutation, sponsored by Mohamed Abdel-Rahman. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Mohamed Abdel-Rahman · Observational

How we know

From the registry’s dates

  • Started Mar 2015; still recruiting 11 years 8 months later.
Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Uveal Melanoma with a site in United States — 26 open to participants now, 51 under way, 7 of them phase 3. Uveal Melanoma · United States.

Planned enrollment
2nd of 18
500 · median 79
Started
2015
with 4 others
Observational
18 of 191
2 open now
Primary completion
2027-07
later than 23 of 50 live
Registered
143rd of 191
by date

Among the 191 studies in Uveal Melanoma with a site in United States, this one is the 2nd largest by planned enrollment of the 18 observational ones that give a count, is one of 5 that started in 2015, is one of 18 observational ones, reaches primary completion later than 23 of the 50 other live ones, and was the 143rd registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

26 of the 191 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screening and earlier intervention which would improve the treatment outcome not only for retaining vision but also for overall survival. Similarly in patients with germline BAP1 mutation CM develops in premalignant atypical melanocytic lesions and careful follow up of these patients will improve the outcome of their disease. In addition this study could have impact on the management of patients with personal and/or family history of several other cancers reported in patients with germline BAP1 mutation such as mesothelioma, renal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, meningioma and basal cell carcinoma.

Read the detailed description

BAP1 (BRCA1-associated protein-1), is a deubiquitinating enzyme with a ubiquitin carboxy-terminal hydrolase function that has been suggested to be a tumor suppressor gene with a role in cell proliferation and growth inhibition. Recently germline mutations in BAP1 have been identified by our group and others in families with hereditary cancers. However, the clinical spectrum of cancers in patients with germline BAP1 is still not clear. The association of germline BAP1 mutations with increased risks for uveal melanoma (UM), mesothelioma, cutaneous melanoma (CM), renal cell carcinoma (RCC) and BAP1-inactivated melanocytic tumors is fairly well established. However, several other cancers have been reported in these patients and their family members including cholangiocarcinoma, hepatocellular carcinoma, meningioma, basal cell carcinoma and other internal malignancies. Identification of the clinical phenotype of BAP1-TPDS is important for proper counseling and management of patients.

03

Conditions studied

  • Uveal Melanoma
  • Cutaneous Melanoma
  • BAP1 Gene Mutation
  • Renal Cell Carcinoma
  • Mesothelioma
  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Meningioma Atypical
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Providers at OSU will identify eligible participants through clinical practice. Providers at other institutions who become aware of our research through presentations at conferences, publications, etc. may identify one of their patients as eligible or potentially eligible for the study and introduce the study to their patient.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who meet any of the following criteria:

  1. Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, meningioma and hepatocellular carcinoma.
  2. Any patient with personal history of at least 2 cancers reported in hereditary BAP1 cancer predisposition syndrome.
  3. Any subject (affected or unaffected) with a documented BAP1 pathogenic/ likely pathogenic variant.
  4. Any patient with a cancer reported in BAP1 and a germline variant of uncertain significance.
  5. At risk relatives of a patient with documented BAP1 mutation.

Exclusion criteria

Exclusion Criteria:

  • Study material including consent forms are currently only available in English so non-English speaking subjects are excluding
05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with personal and/or family history suggestive of hereditary BAP1

    Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, hepatocellular carcinoma and meningioma

  • Pathogenic, likely pathogenic variants in BAP1 and variants of uncertain significance

    Affected and unaffected individuals with pathogenic or likely pathogenic variant in BAP1 and their family members Patients with personal family history of any of the BAP1 associated cancer and a variant of uncertain significance of BAP1

06

What researchers measure

Primary outcomes

  1. Prevalence of germline BAP1 variants in the unselected general population of cancer patients

    Frequency of germline BAP1 pathogenic/likely pathogenic variants in different cancers

    Time frame: 5 years

  2. Clinical phenotypes (this includes premalignant lesions, tumor type and age of onset) in at risk blood-line family members of the patients

    Questionnaire and chart review of the clinical phenotype

    Time frame: 5 years

Secondary outcomes

  1. Questionnaire to assess environmental risk factors modifying cancer risk in patients

    Measurement used: questionnaire for various environmental risk factors

    Time frame: 10 years

  2. Genotyping to assess genetic risk factors modifying risk of cancer

    Genotyping for genetic variants that could modify the risk of cancer in subjects.

    Time frame: 10 years

  3. Disease outcome (response to treatment, prognosis including prognostic markers)

    Chart review of disease outcome

    Time frame: 10 years

  4. Tumor pathology and genomics (including tumor grade, stage, somatic genomic alterations)

    Review of pathology and study of genomics alterations in tumors

    Time frame: 10 years

  5. Assessment of disease penetrance and life time risk estimate

    Statistical assessment of disease penetrance and life time risk estimates of various cancers

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Godwin K, McElroy J, Senter L, Byrne L, Abdel-Rahman MH. Patient-derived outcome assessment of knowledge, communication, and management in those diagnosed with BAP1-tumor predisposition syndrome. Fam Cancer. 2026 Mar 17;25(2):28. doi: 10.1007/s10689-026-00541-8. PubMed 41843333 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2015 (actual). Primary completion is estimated for Jul 2027, 147 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2021
First posted
Mar 11, 2021
StartActual
Mar 3, 2015
Primary completionEst.
Jul 1, 2027was Jul 2026
CompletionEst.
Jul 1, 2027was Jul 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 1, 2026→Jul 1, 2027
Oct 16, 2026
Study completion
Jul 1, 2026→Jul 1, 2027
Oct 16, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41843333 ↗
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41843333 ↗
    Primary completion Jul 1, 2026→Jul 1, 2027
    Study completion Jul 1, 2026→Jul 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04792463
Lead sponsor
Mohamed Abdel-Rahman
Responsible party
Mohamed Abdel-Rahman (Associate Professor, Ohio State University) — Sponsor-investigator
First posted
Mar 11, 2021
Start date
Mar 3, 2015
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Mohamed H Abdel-Rahman, MD, PhD
Contact
Mohamed.Abdel-Rahman@osumc.edu
614-292-1396
Mohamed H Abdel-Rahman, MD, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion